Last updated on July 2019

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder


Brief description of study

The purpose of this study is to evaluate the efficacy and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

Detailed Study Description

The present study (CL3-95008-001) will be performed in children and adolescents from 7 to less than 18 years old presenting with ASD. A 6-month double-blind treatment period will be performed in which efficacy and safety of bumetanide 0.5mg BID will be assessed versus placebo. This double-blind period will be followed by a 6-month open label treatment period of bumetanide 0.5mg BID in which long term safety will be evaluated.

Clinical Study Identifier: NCT03715166

Find a site near you

Start Over

CHU Rouen

Rouen, France
  Connect »

Accare Groningen

Groningen, Netherlands
  Connect »

The Winnicott Centre

Manchester, United Kingdom
  Connect »

Liverpool Hospital

Liverpool, Australia
  Connect »

ReCognition Health

London, United Kingdom
  Connect »